Vitaeris
About:
Canadian clinical-stage biopharmaceutical company
Website: http://www.vitaerisbio.com/
Twitter/X: vitaerisbio
Top Investors: HBM Healthcare Investments
Description:
Vitaeris has licensed global exclusive rights to the best-in-class anti-interleukin-6 monoclonal antibody Clazakizumab from Alder Biopharmaceuticals, and is actively pursuing innovative applications in chronic inflammatory diseases.
Total Funding Amount:
$7M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Vancouver, British Columbia, Canada
Founded Date:
2016-01-01
Contact Email:
info(AT)vitaerisbio.com
Founders:
Kevin Chow, Noel Hall, Patrick Robinson
Number of Employees:
11-50
Last Funding Date:
2016-06-06
IPO Status:
Private
Industries:
© 2025 bioDAO.ai